Skip to main content
Fig. 4 | BMC Biotechnology

Fig. 4

From: Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice

Fig. 4

Effect of PEG-FGF21 and FGF21 on serum P-creatinine and urinary albumin/creatinine ratio in DIO mice. The levels of serum P-creatinine were measured after chronic treatment with PEG-FGF21 and FGF21 (a); A 24-h urine sample was collected after FGF21 and PEG-FGF21 administration and urinary albumin/creatinine ratio was determined (b). Statistical analysis was performed between groups at the same time periods; Data are means ± SEM; *P ≤ 0.05, vs. DIO + FGF21. n = 10

Back to article page